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Abstract
In Drosophila, the CASZ1 (castor) gene encodes a zinc finger transcription factor and is a neural fate-determination gene. In
mammals, the CASZ1 gene encodes two major isoforms, CASZ1a with 11 zinc fingers and CASZ1b with 5 zinc fingers.
CASZ1b is more evolutionally conserved since it is the only homologue found in drosophila and Xenopus. Our previous study
showed that full length CASZ1 (CASZ1a) functions to suppress growth in neuroblastoma tumor. However, the function of
CASZ1b isoform in mammals is unknown. In this study, realtime PCR analyses indicate that mouse CASZ1b (mCASZ1b) is
dynamically expressed during neurogenesis. CASZ1b and CASZ1a co-exist in all the neuronal tissues but exhibit distinct
expression patterns spatially and temporally during brain development. CASZ1b and CASZ1a expression is coordinately
upregulated by the differentiation agent Retinoic Acid, as well as agents that modify the epigenome in neural crest derived
neuroblastoma cell lines. In contrast CASZ1b is down regulated while CASZ1a is upregulated by agents that raise
intracellular cAMP levels. CASZ1b and CASZ1a have no synergistic or antagonistic activities on the regulation of their target
NGFR gene transcription. Specific restoration of CASZ1b in NB cells suppresses tumor growth in vitro and in vivo. Consistent
with its function role, we find that low CASZ1b expression is significantly associated with decreased survival probability of
neuroblastoma patients (p,0.02). This study indicates that although their mechanisms of regulation may be distinct, both
CASZ1b and CASZ1a have largely redundant but critical roles in suppressing tumor cell growth.
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Introduction
CASZ1/Castor (Cas) gene was first characterized in drosophila
where it encodes a zinc finger transcription factor that functions to
regulate neural fate. Loss of Cas in Drosophila impairs differen-
tiation and alters glial cell number and migration [1,2,3,4]. In
Xenopus, CASZ1 is required for heart development and the onset of
cardiomyocytes differentiation at the ventral midline [5]. In
humans, the CASZ1 gene localizes to chromosome 1p36, and
deletion of this region frequently occurs in cancers such as
neuroblastoma, melanoma, oligodendroglioma and breast cancers
[6]. We have characterized two isoforms of CASZ1 gene from
human, CASZ1a and CASZ1b [7]. CASZ1a, the full length
isoform, comprises 1759 amino acids (AA) with 11 TFIIIA class
C2H2 zinc finger; CASZ1b comprises 1166 AA that are identical
to the first 1166 AA of CASZ1a but lacks the last 6 zinc fingers, so
when described they were named hcasz11 and hcasz5, respectively
[7]. A murine in situ hybridization study showed that total CASZ1
exhibits a dynamic expression pattern during neurogenesis [8], but
the specific and quantitative expression of CASZ1a and CASZ1b
isoforms has yet to be investigated. Recently we have shown that
full length CASZ1 (CASZ1a isoform) functions as a neuroblastoma
tumor suppressor [9], however a functional role for the CASZ1b
has not been described to date.
The generation of multiple isoforms from a single gene, is
believed to contribute to the complexity of higher organisms by
enabling additional regulatory controls and insuring the accuracy
of cellular signaling programs. Consequently, when studying the
function of a given gene, it is imperative to delineate the functional
potential of the corresponding protein products. For example,
neuron-restrictive silencer factor (NRSF) silences neuronal genes
expression, while its truncated variant sNRSF (or REST4) that
lack the NRSF C-terminal region act as an activator rather than
repressor of the transcriptome regulated by NRSF [10]. The
tumor suppressor gene p73 has multiple isoforms with distinct
functions with the transcriptionally active Tap73 isoform having a
pro-apoptotic function and the DNp73 isoform functioning as a
dominant negative, to attenuate TAP73 function and exerts anti-
apoptotic functions [11]. However, there are also many cases in
which the isoforms generated from a single gene play redundant
roles. The p16c is an alternate transcript of p16
INK4A and is co-
expressed with p16
INK4A in cancer cells; p16c functions indistin-
guishably from wild-type p16
INK4A with respect to CDK
interactions and inhibition cell-cycle arrest and growth inhibition
[12]. Two spliced forms of SEMA3F share common axonal
chemorepulsive properties and are functionally redundant at
regulating endothelial cell morphology in vitro [13]. We recently
demonstrated that low total CASZ1 expression is associated with
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18557poor prognosis in neuroblastoma patients and the full length
isoform CASZ1a suppresses neuroblastoma growth in vitro and in
vivo [9], however it is important and necessary to assess the
function of CASZ1b.
In drosophila and Xenopus, the predominant Cas isoform is
homologous to CASZ1b. In human we have shown that CASZ1a
and CASZ1b mRNA are the two major isoforms expressed in
human cell lines as well as in adult human tissues such as heart and
skeletal muscle by northern analysis [7]. A high degree of
homology is found for both CASZ1a and CASZ1b protein in
species like Mus musculus, Rattus norvegicus and Canis familiaris, and
they share over 90% identity for either isoform (unpublished data).
However, the nature of the functional relationship between
CASZ1a and CASZ1b is not known. In this study, we find that
CASZ1a and CASZ1b are dynamically expressed during neuro-
genesis and their expression is coordinately regulated during
differentiation. CASZ1b has no synergistic or antagonistic
activities to CASZ1a on gene transcription regulation. Primary
neuroblastoma tumors that have either low CASZ1a or low
CASZ1b have a poor outcome. Consistently, CASZ1b like
CASZ1a is capable of suppressing neuroblastoma tumor growth.
Results
CASZ1a and CASZ1b are dynamically expressed during
neurogenesis and are coordinately regulated in vitro
CASZ1a and CASZ1b are encoded by the CASZ1 gene and
generated by the use of two alternative polyadenylation sites and
subsequent alternative splicing of exon 16. The CASZ1b protein
lacks the last 6 zinc fingers and the C-terminus of the full length
CASZ1a (Figure 1A). While total CASZ1 expression has been
detected in the mouse nervous system by in situ hybridization [8],
we quantitatively investigated the isoform specific expression of
mouse CASZ1a (mCASZ1a) and CASZ1b (mCASZ1b) during
neurogenesis, by designing primer pairs that target the mCASZ1a
39-UTR and mCASZ1b 39-UTR and performing real-time PCR
(RT-PCR). The expression pattern of mCASZ1a and mCASZ1b
in various neuronal tissues during neurogenesis is shown in
Figure 1B. The mCASZ1a and mCASZ1b isoforms exhibit a
dynamic expression pattern in all neuronal tissues evaluated
including Telencephalon, Mesencephelon, Rhombencephalon,
Midbrain, Pons, Frontal Cortex, Posterior Cortex, Enthorhinal
Cortex, Olfactory Bulb, Hippocampus, Striatum, Thalamus,
Hypothalamus, Cerebellum, Medulla and Spinal cord. The
relative mCASZ1a and mCASZ1b expression levels were higher
in the early stages (E13 and E15) and decreased in the later stage
(adult). Both mCASZ1a and mCASZ1b isoforms are highly
expressed in the medulla and spinal cord (Figure 1B). Peak levels of
the mCASZ1a isoform were detected in the Spinal cord at E15
which was 1.5-fold higher than in E13, 2-fold higher than in E18
and 12-fold higher than in adult. mCASZ1b level in Spinal cord
peaked at E13, it is 1.8-fold higher than in E18 and 3.7-fold higher
than in adult (Figure 1B).
The mCASZ1a and mCASZ1b isoforms are co-expressed in
neuronal tissues with a relatively higher level of mCASZ1a
compared to mCASZ1b. The ratio of mCASZ1a to mCASZ1b
(mCASZ1a/mCASZ1b) in different tissues varied from 1.3-fold (in
adult Spinal cord) to 15-fold (in P6 posterior cortex) (Figure 1C).
The ratio of mCASZ1a to mCASZ1b varied during development
in different neuronal tissues. In the medulla, the mCASZ1a/
mCASZ1b isoform ratio kept decreasing, from 10.5-fold in E15 to
1.6-fold in adult (Figure 1C, a). The mCASZ1a/mCASZ1b
isoform ratio variation exhibits a similar pattern in some neuronal
tissues during development and selected ones are shown in
Figure 1C (Panels, b, c and d). These data suggest that the two
isoforms might play a distinct role, work in concert to control the
neuronal subtype specification and differentiation or be subject to
different regulatory stimuli.
The co-existence of mCASZ1a and mCASZ1 during neuro-
genesis suggests that they are coordinately regulated. To evaluate
this we tested how epigenetic modulation or induction of
differentiation affected CASZ1a and CASZ1b expression regula-
tion in human neural crest derived neuroblastoma cells. After
neuroblastoma cells were treated with the DNA demethylating
agent 5-Aza-dC for 3 days, CASZ1a mRNA level was induced
2.2-3.5 fold in the NB cell lines tested while CASZ1b mRNA level
was up-regulated 1.5-3 fold (Figure 2A). Treatment with the
HDAC inhibitor depsipeptide (a Type I HDAC inhibitor) caused a
11-fold increase in CASZ1a mRNA level and 4-fold increase in
CASZ1b mRNA level in NGP cells after 3 days (Figure 2B).
Induction of SY5Y neuroblastoma cell differentiation with RA for
3 days was accompanied by 7-fold increase in CASZ1a mRNA
level and 2-fold increase in CASZ1b mRNA level (Figure 2C).
Using an alternative differentiation model we found that there was
71-fold increase in CASZ1a mRNA level and 18-fold increase in
CASZ1b mRNA level in C2C12 myoblasts induced to differen-
tiated into myotubes (Figure 2D). In contrast, we found 50%
decrease in CASZ1b and 3.5-fold increase in CASZ1a mRNA
level when KCNR cells were treated with agents that raise
intracellular cAMP (Figure 2E).
CASZ1a and CASZ1b are coexpressed and coordinately
regulated at protein level
To assess CASZ1a and CASZ1b expression at the protein level,
we utilized an affinity-purified anti-CASZ1 peptide antibody,
which recognizes an epitope (AA 923-936) shared by both
CASZ1a and CASZ1b. Our first level of evaluation was to test
whether the antibody recognizes the exogenously expressed
CASZ1a and CASZ1b proteins. FLAG-tagged CASZ1a and
CASZ1b in Tet-on vector was stably transfected into SY5Y
neuroblastoma cell lines that express Tet repressor (SY5Ytet-
CASZ1a cells or SY5YtetCASZ1b cells). Whole protein lysates
from SY5YtetCASZ1a or SY5YtetCASZ1b clones cultured in the
absence or presence of 1ug/ml tetracycline (TET) were separated
on a 4–12% SDS-page gel and transferred to a nitrocellulose
membrane. Induction of CASZ1a and CASZ1b expression by
TET was visualized by immunoblotting whole cell lysate with the
affinity-purified rabbit anti-CASZ1 antibody; however, no
CASZ1a or CASZ1b band was seen in control lanes (non-TET
treated) (Figure 3A, left). Endogenous CASZ1a and CASZ1b
expression in BE2 cell line were detected using the anti-CASZ1
antibody; and the specificity of the anti-CASZ1 antibody was
demonstrated by pre-incubation of the antibody with immunizing
peptide followed by immunoblotting analysis (Figure 3A, right).
We saw two bands at CASZ1a’s relative molecular weight of
220KD in BE2 cell lysates. The extra band might be a post-
translation modification (such as phosphorylation) of CASZ1a
protein. Endogenous CASZ1a and CASZ1b are also predomi-
nantly expressed in the nucleus (Figure 3B, upper panel) consistent
with our findings for transfected CASZ1 [7]. Prior incubation of
the anti-CASZ1 antibody with the immunizing peptide blocked
CASZ1 staining demonstrated the specificity of this staining
(Figure 3B bottom panel).
To determine the CASZ1 gene expression pattern in normal
tissues, whole protein lysates from P6 mouse tissues were separated
by on 4–12% SDS-page gel and western blot analysis was
performed using anti-CASZ1 antibody. We found that mouse
CASZ1a and CASZ1b proteins are co-expressed in heart, lung
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PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e18557Figure 1. Mouse CASZ1a (mCASZ1a) and CASZ1b (mCASZ1b) co-exist during neurogenesis and exhibit different patterns of
expression. A. CASZ1a and CASZ1b transcript structure (top). Exon 16 is differently spliced to produce these two transcripts; CASZ1a and CASZ1b
protein structure (bottom); CASZ1b lacks the C-terminal region of CASZ1a, which includes 6 zinc fingers. B. mCASZ1a and mCASZ1b mRNA level in
neuronal tissues were detected by real time PCR using mCASZ1a and mCASZ1b specific primers. The two isoforms are dynamically expressed in the
nervous system during development with mCASZ1a having a relatively higher level of expression compared to mCASZ1b. C. The ratio of mCASZ1a
and mCASZ1b mRNA varied during development in different regions of the brain: a. Medulla; b. Frontal, Posterior, Enthorithinal cortex and
Hippocampus; c. Hypothalamus, Olfactory bulb; d. Midbrain, Spinal cord, Thalamus, Pons and Striatum.
doi:10.1371/journal.pone.0018557.g001
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regulated about 2-fold by RA treatment of BE2 cells or almost 3-
fold by 5-Aza-dC treatment of NGP cells (Figure 3D). These data
demonstrate that CASZ1a and CASZ1b are co-expressed and
coordinately regulated at both the mRNA and protein levels.
CASZ1b is neither a dominant negative nor a synergistic
factor of CASZ1a at regulating gene expression
CASZ1b and CASZ1a induce NGFR and Tyrosine Hydrox-
ylase (TH) in SY5Y cells as well as HEK293T cells (Fig 4A, B)
upon transfection of either CASZ1b or CASZ1a. Moreover,
similar results are found for activation of the TH promoter in
HEK293T cells (Figure 4C). Thus both isoforms are functionally
equivalent in inducing TH and NGFR. This suggests that the
short isoform CASZ1b is not a dominant negative of the longer
CASZ1a isoform. To more formally assess the synergistic or
antagonistic activities of the CASZ1 isoforms we co-transfected
CASZ1a and CASZ1b plasmids into HEK293T cells and assessed
the expression of NGFR by RT- PCR. NGFR mRNA expression
was induced by CASZ1a, and increasing the amount of the
transfected plasmid (from 0.5 mgt o2mg) resulted in a stronger
induction (4-fold to 30-fold) (Figure 4D). The fold induction of
NGFR by CASZ1a plus CASZ1b was similar to the fold induction
of NGFR by a single isoform (or the average of the two isoforms)
when controlling for the total amount of plasmid. This occurred
even when different ratios of CASZ1a and CASZ1b isoform
Figure 2. CASZ1a and CASZ1b are coordinately regulated. A. Neuroblastoma cell lines were treated with 2 mM demethylating agent 5-Aza-dC
for 3 days. Both CASZ1a and CASZ1b mRNA levels were upregulated in KCNR, NGP and SY5Y as detected by RT-PCR using CASZ1a and CASZ1b
specific primer (all p,0.02). B. NGP cells were treated with the class I histone deacetylase inhibitor, depsipeptide (5 ng/ml) for 24 hr. Both CASZ1a
and CASZ1b mRNA levels were up-regulated by depsipeptide as detected by RT-PCR (all p,0.0002). C. Both CASZ1a and CASZ1b mRNA levels were
up-regulated by 5 mM RA in SY5Y cells as detected by RT-PCR (all p,0.05). D. Both mCASZ1a and mCASZ1b mRNA levels were up-regulated when
mouse C2C12 cells are cultured in 2% horse serum for 4 days or 8 days as detected by RT-PCR (all p,0.001). E. CASZ1b mRNA levels was down-
regulated and CASZ1a mRNA levels was up-regulated by 2 mM dibutyryl cyclic AMP treatment for 48 hr in KCNR cells as detected by RT-PCR (all
p,0.05).
doi:10.1371/journal.pone.0018557.g002
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CASZ1a and CASZ1b have neither antagonistic nor synergistic
activities on NGFR gene transcription regulation.
Either low CASZ1a or CASZ1b is associated with poor
prognosis in Neuroblastoma
Our previous RT-PCR analysis showed that low expression of
total CASZ1 is significantly correlated with decreased survival
probability [9]. However, since the ratios of the two isoforms are
often different under different conditions we sought to evaluate
their expression pattern in primary tumors from neuroblastoma
patients. We evaluated CASZ1a and CASZ1b mRNA expression
in 59 primary neuroblastoma patients’ tumors by real-time PCR
using CASZ1a and CASZ1b specific primers. We found that both
CASZ1a and CASZ1b mRNA are detected in all of the tested
primary neuroblastoma tumors. The relative level of CASZ1a was
higher than CASZ1b in the majority of the samples (Figure 5A)
and the mean steady-state level of CASZ1a was approximately 2-
fold higher than CASZ1b (Figure 5B).
The median values of CASZ1b (0.9468) and CASZ1a (0.9195)
expression were used to dichotomize the patients into two groups
(, median vs. $ median). Tests of association of dichotomized
CASZ1b and CASZ1a with age, International Neuroblastoma
Staging System (INSS) stage, risk, MYCN status, Shimada
histology, ploidy, 1p loss of heterozygosity (LOH), and 11q
LOH were performed (Table 1, 2). Statistically significant
associations were found between all factors except ploidy for
CASZ1b (Table 1), and except age and ploidy for CASZ1a
(Table 2). In all the statistically significant cases, high expression of
CASZ1 isoforms was associated with the more beneficial level of
the factor (,18 months, not stage 4, low or intermediate risk, non-
amplified MYCN, favorable Shimada histology, no 1p LOH)
except with 11q, which was reversed. The patients with high
CASZ1b had a statistically significantly better EFS (p=0.0279)
and OS (P=0.0199) than that for patients with low CASZ1b
expression (Figure 5C, E). Similarly, patients with high CASZ1a
expression had statistically significantly better EFS (p=0.0252)
and OS (p=0.0179) than that for patients with low hCASZ11
expression (Figure 5D, F).
Like CASZ1a, CASZ1b suppresses neuroblastoma cell
proliferation
The similarities in transcriptional activity by the CASZ1
isoforms suggest that these isoforms may also have similar
functions. Previously we found that CASZ1a suppresses neuro-
blastoma cell proliferation [9] and in this study, we found that
upon CASZ1b induction, neuroblastoma cell proliferation was
inhibited ,80% in SY5Y cells by either a cell confluence assay or
MTS assay. Growth of the empty vector control cell lines was not
affected by Tet treatment (Figure 6A, B).
To test whether CASZ1b inhibits tumorigenicity of neuroblasto-
ma cells, anchorage-independent growth was assessed by soft agar
Figure 3. CASZ1a and CASZ1b are co-expressed and coordinately regulated at the protein level. A. Anti-CASZ1 antibody is specific to
CASZ1a and CASZ1b. Induction of CASZ1a and CASZ1b expression in the SY5YtetCASZ1a and SY5YtetCASZ1b clones by Tet at 24 hours was
visualized by immunoblotting the cell lysates with anti-CASZ1 antibody (left); endogenous CASZ1a and CASZ1b expression in neuroblastoma cells
was visualized by immunoblotting the BE2 cell lysates with anti-CASZ1 antibody, and the specificity of the antibody was demonstrated by pre-
incubation of immunizing peptide and loss of CASZ protein recognition with immunoblotting analysis (right). B. Endogenous CASZ1a and CASZ1b
are predominantly expressed in the nucleus of neuroblastoma cells. The nuclear localization of CASZ1a and CASZ1b was characterized by the co-
localization of Alex 568-labeled goat anti-mouse IgG and DAPI-stained nucleus of BE2 cells (top), and the specificity of the antibody was
demonstrated by the blocking effect of antigen peptide on antibody recognition with immunoblotting analysis (bottom). C. The co-expression of
murine CASZ1a and CASZ1b protein in heart, lung and eye of P6 mouse was visualized by immunoblot analysis of tissue lysates using an anti-CASZ1
antibody. D. The simultaneous up-regulation of CASZ1a and CASZ1b protein by either RA or 5-Aza-dC in neuroblastoma cell lines was visualized by
immunoblot analysis of the cell lysates using the anti-CASZ1 antibody.
doi:10.1371/journal.pone.0018557.g003
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to CASZ1a clones, the CASZ1b expressing cells showed an over
90% decrease in soft agar clonogenicity compared to the controls
(Figure 6C). To assess in vivo tumorigenicity, SY5YtetCASZ1b cells
were implanted at a subcutaneous site into mice that had received
normal food or doxycycline containing food during the prior week (5
mice per group). Doxycycline-treated animals showed decreases in
tumorgrowth.Aninhibitionoftumorgrowthof90%wasdetectedat
the 9
th week compared to placebo-treated mice (Figure 6D).
Discussion
The generation of multiple isoforms from a single gene ensures
the accuracy of cellular signaling programs and enables additional
regulatory controls. We describe here the characterization of an
evolutionarily conserver, short alternatively spliced isoform of the
CASZ1 gene, CASZ1b. CASZ1b isoform lacks 1/3 of the C-
terminal region of the full length CASZ1a isoform. Expression of
CASZ1b is detected in all CASZ1a-expressing neuroblastoma
samples and mouse tissues. CASZ1a and CASZ1b are coordi-
nately regulated when neuroblast and myoblast cells are induced
to differentiate, but the two CASZ1 isoforms are characterized in
vivo by a temporal and regional specific regulation during
neurogenesis. Functionally, CASZ1b behaves similar to CASZ1a
at regulating gene expression and the co-expression of CASZ1b
and CASZ1a shows neither cross antagonistic or synergistic
activities. Moreover low CASZ1b or CASZ1a expression is
associated with poor prognosis of neuroblastoma patients and
Figure 4. There is no antagonist or synergistic effect between CASZ1b and CASZ1a at the level of gene transcription. A. Induction of
NGFR and TH expression in the SY5YtetCASZ1a and SY5YtetCASZ1b clones after induction of CASZ1a and CASZ1b by Tet at 24 hours was confirmed
by real time PCR (all p,0.01). B. pCMVTag2A empty vector (EMV) or pCMVTag2A-CASZ1a (pCMVtag2A-CASZ1b) was transiently transfected into 293T
cells, and the fold induction of NGFR and TH by CASZ1a or CASZ1b compared to EMV at 24 hr was detected by real time PCR (all p,0.01). C. TH-
Luciferase construct was activated by CASZ1b and CASZ1a 24 hours after transfection of HEK293T cells at 24 hr (p,0.0005). D. The degree of NGFR
induction by co-transfection of CASZ1b plus CASZ1a into HEK293T cells is similar to the cells that were transfected by single isoform.
doi:10.1371/journal.pone.0018557.g004
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suppressing neuroblastoma cells growth in vitro and in vivo.
CASZ1 in drosophila is a neuronal fate-determination gene and
controls the nervous system development [1,2,4]. There are highly
evolutionarily conserved DNA elements in the noncoding region
of CASZ1 gene from drosophila to human [14,15,16]. The highly
conserved noncoding elements are strongly associated with
developmental regulatory genes [16,17] suggesting that CASZ1
must be playing some fundamental role in mammalian nervous
system development as well. In this study, we find that during
neurogenesis, mouse CASZ1 (mCASZ1a) and CASZ1b
(mCASZ1b) exhibits a dynamic expression pattern. Both
mCASZ1a and mCASZ1b are expressed at a relatively higher
levels during early development (E13, E15) compared to a later
stages or in adults (P6, adult), and the levels vary in different
neuronal subtypes as well (Figure 1B). The spatial and temporal
Figure 5. Loss of either CASZ1b or CASZ1a expression is correlated with poor prognosis in neuroblastoma. A. CASZ1a and CASZ1b
have similar expression patterns in primary neuroblastoma samples. B. The average of CASZ1a mRNA level is about 2-fold higher than CASZ1b
(p,0.002). C. Kaplan-Meier curves of EFS for low (,0.9468) vs. high ($0.9468) CASZ1b expression in 59 neuroblastoma patients. D. Kaplan-Meier
curves of EFS for low (,0.9195) vs. high ($0.9195) CASZ1a expression in 59 neuroblastoma patients. E. Kaplan-Meier curves of OS for low (,0.9468)
vs. high ($0.9468) CASZ1b expression in 59 neuroblastoma patients. F. Kaplan-Meier curves of OS for low (,0.9195) vs. high ($0.9195) CASZ1a
expression in 59 neuroblastoma patients (all p,0.05).
doi:10.1371/journal.pone.0018557.g005
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genesis suggest an important role in the control of neuronal
subtype specification, differentiation and neuronal migration.
Although mCASZ1a and mCASZ1b are co-expressed in all the
tested neuronal tissues, their ratios vary at spatially and
temporally. (Figure 1C). It is possible that there is a modulating
role between mCASZ1b and mCASZ1a in the control of nervous
system development, and this modulating role is dependent on the
ratio between these two isoforms.
The co-existence of CASZ1a and CASZ1b suggests the two
isoforms are coordinately regulated. In the in vitro models we find
that the two isoforms are simultaneously upregulated when
neuroblastoma cells or myoblast cells are induced to differentiate
by RA or 2% horse serum (Figure 2 A–D), which is consistent with
the bioinformatic assay that CASZ1a and CASZ1b share the same
promoter. We find that the induction of CASZ1a at mRNA level is
greater than the induction of CASZ1b in the in vitro model and
CASZ1a mRNA level is higher than CASZ1b in the mouse
neuronal tissues, suggesting CASZ1a and CASZ1b mRNA have
different stability or there is a different post-transcriptional
regulation. microRNA (miRNA) are post-transcriptional regula-
tors that target 39UTR to control gene expression by degrading or
repressing target mRNAs [18]. Using an online miRNA search
tool (http://www.microrna.org/microrna/getGeneForm.do), we
find that there are 26 conserved miRNAs with good mirSVR
scores that target CASZ1a mRNA 39UTR (NM_001079843).
There are 26 unique miRNAs target CASZ1b mRNA 39UTR
(NM_017766), which are different from those miRNAs that target
CASZ1a (unpublished data). So CASZ1a or CASZ1b mRNA
levels may be regulated by the tissue and cell type specific
expression of miRNAs. Agents that raise intracellular cAMP
decrease CASZ1b and increase CASZ1a mRNA levels (Figure 2E)
suggesting that the cAMP pathway might regulate CASZ1 mRNA
stability through miRNAs. Consistent with CASZ1 expression
pattern, miRNA plays a central role to control neurogenesis and
tumorigenesis [18,19]. A future study will focus on identifying
bona-fide miRNAs targets to CASZ1a and CASZ1b to fully
understand the regulation of their expression during neurogenesis.
Frequently different isoforms from a single gene have distinct
functions. For example, the full length TAp73 and the DNp73
isoforms are transcribed from the p73 gene. The DNp73 isoform
acts as a dominant-negative inhibitor of TAp73 to prevent target
Table 1. Association of CASZ1b and CASZ1a Expression Level
with Prognostic Factors (n=59).
Factor n
Number (%) of Patients
with CASZ1b Expression
$ 0.9468 (median) p-value
*
Age
,18 months 33 22 (67) 0.0038
$18 months 26 7 (27)
INSS Stage
1,2,3,4s 32 20 (63) 0.0370
4 27 9 (33)
Risk Group
Low/Intermediate 30 21 (70) 0.0017
High 29 8 (28)
MYCN
Not amplified 39 26 (67) 0.0003
Amplified 20 3 (15)
Shimada histology
Favorable 27 21 (78) 0.0002
Unfavorable 29 8 (28)
Unknown 3
Ploidy
Hyperdiploid 38 22 (58) 0.1033
Diploid 21 7 (33)
1p
No LOH 39 25 (64) 0.0030
LOH 17 3 (18)
Unknown 3
11q
No LOH 39 15 (38) 0.0186
LOH 17 13 (76)
Unknown 3
*From 2-sided Fisher’s Exact Test.
doi:10.1371/journal.pone.0018557.t001
Table 2. Association of CASZ1b and CASZ1a Expression Level
with Prognostic Factors (n=59).
Factor n





,18 months 33 20 (61) 0.0673
$18 months 26 9 (35)
INSS Stage
1,2,3,4s 32 20 (63) 0.0370
4 27 9 (33)
Risk Group
Low/Intermediate 30 21 (70) 0.0017
High 29 8 (28)
MYCN
Not amplified 39 26 (67) 0.0003
Amplified 20 3 (15)
Shimada histology
Favorable 27 18 (67) 0.0372
Unfavorable 29 11 (38)
Unknown 3
Ploidy
Hyperdiploid 38 22 (58) 0.1033
Diploid 21 7 (33)
1p
No LOH 39 25 (64) 0.0083
LOH 17 4 (24)
Unknown 3
11q
No LOH 39 14 (36) 0.0030
LOH 17 14 (82)
Unknown 3
*From 2-sided Fisher’s Exact Test.
doi:10.1371/journal.pone.0018557.t002
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CASZ1b into HEK293T cells have the same effect as transfection
of CASZ1a alone on the target NGFR gene expression (Figure 4)
indicating that there is no synergistic or antagonistic effect on a
target gene between CASZ1a and CASZ1b. In the transient
transfection experiment, overexpression CASZ1a in HEK293T
cells induces more NGFR and TH than CASZ1b does (Figure 4B,
C), suggesting that CASZ1a may enable more active transcription
from a target gene. This may be because the extra 6 zinc fingers of
CASZ1a stabilize the DNA binding or recruit more co-activators
to enhance gene transcription. CASZ1a is a neuroblastoma tumor
suppressor gene that suppresses tumor growth in vitro and in vivo
[9]. Upon restoration of CASZ1b expression in neuroblastoma
cells we find that like CASZ1a, CASZ1b suppresses tumor growth
(Figure 6). Consistently, we find low CASZ1a or CASZ1b are
associated with poor prognosis of neuroblastoma patients
(Figure 5), which is similar to what we find for total CASZ1 [9].
There is evidence that isoforms generated from a single gene
may play redundant roles. The p16c is an alternate transcript of
p16
INK4A and co-expresses with p16
INK4A in cancer cells; p16c
functions similarly to wild-type p16
INK4A at inhibiting cell growth
[12]. Two spliced forms of SEMA3F are functionally redundant at
regulating endothelial cell morphology in vitro although they are
differentially expressed in nervous system [13]. Another more
commonly recognized example is Wilm’s tumor gene, WT1,
which encodes up to 24 different isoforms which have distinct but
also overlapping cellular and developmental functions [20]. Our
results suggest CASZ1a and CASZ1b function similarly at
regulating gene transcription and suppressing tumor growth.
These findings provide fundamental information for the future
study of the association of CASZ1 gene encoded proteins with
pathogenesis.
In the context of gene transcription regulation and tumor
growth, we found that the CASZ1a and CASZ1b isoforms play
redundant roles. It is possible that either isoform has the capacity
to compensate for each other’s loss during normal development;
when one isoform is accidently degraded or silenced; the other
isoform may undertake the role. We believe that this redundant
expression and largely overlapping functions of CASZ1a and
CASZ1b isoforms indicate that expression of the CASZ1 gene is
an important regulator of normal development. In fact, it has been
proposed that redundancy as a conserved design of genetic
networks [21]. While we find similarities in function this is limited
by our knowledge of CASZ1’s known functions as delineated in in
vitro studies. It is possible that they have distinct yet unknown
functions. CASZ1b lacks the C-terminal region of CASZ1a, which
containing 6 zinc fingers, this may result in changes in the three-
dimensional differences for the two isoforms. The unique six zinc
fingers of CASZ1a might contribute its specific protein-DNA
binding or protein-protein interaction role; and the potential
differential post-translation modifications of CASZ1a and
CASZ1b isoforms such as phosphorylation or ubiquitination
may also contribute to their distinct role in a different context.
Further investigation to pursue these possibilities may be
warranted.
In summary, we have reported the functional characterization
of the short isoform of CASZ1 gene, CASZ1b. CASZ1b functions
similar to the full length isoform CASZ1a at regulating gene
expression, suppressing neuroblastoma cell growth in vitro and in
vivo. CASZ1b does not play synergistic or antagonistic role to
CASZ1a based on gene transcription regulation. We conclude that
the evolutionarily conserved CASZ1b isofom also functions as a
candidate tumor suppressor. The neuronal tissue-specific patterns
of expression and regulation of CASZ1a and CASZ1b suggest the
two isoforms may play a fundamentally similar role but at different
times and in different cell types. Future studies of CASZ1a or
CASZ1b specific knock out or transgenic mouse will provide
further insight into our understanding of the relationship between
CASZ1a and CASZ1b and their importance during neurogenesis
and how low levels impact tumorigenesis.
Materials and Methods
Cell culture
Human neuroblastoma cell lines SK-N-BE2 (BE2), SMS-
KCNR, NGP and SH-SY5Y (SY5Y) were cultured in RPMI
1640 supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 mnit/ml penicillin and 100 mg/ml streptomycin as
described previously [7,9]. Mouse C2C12 myoblasts were
maintained in DMEM supplemented with 10% fetal bovine
serum, 50 U/ml penicillian, and 50 mg/ml streptomycin [7]. To
induce C2C12 cell differentiation, the cells were plated into 6-well
plate, 24 hr later when cells were 80% confluent, the medium was
switched to the differentiation medium containing DMEM and
2% horse serum, which was changed every other day. Human
HEK293T cells were obtained from ATCC company (Manassas,
VA, USA), and the cells were cultured in Dulbecco’s modified
Eagle’s media, supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 mnit/ml penicillin and 100 mg/ml streptomycin.
Stable clones
Full-length FLAG-tagged CASZ1 (CASZ1a) cDNA and FLAG-
tagged short isoform CASZ1 (CASZ1b) were cloned into the
tetracycline (Tet) inducible vector pT-REx-DEST30. The control
vector pDest-30 with an out-of-frame CAT gene with no start
codon served as the empty vector control.
Tetracycline (Tet)-inducible expression is dependent on expres-
sion of the Tet repressor in the recipient cells. Recipient cells have
been prepared by stable transfection of the pcDNA6/TR (Tet
repressor) plasmid (Invitrogen) into SY5Ytet12 cells [22] that are
selected with blasticidin. CASZ1a or CASZ1b in pT-REx-
DEST30 or an empty vector control were transfected into
SY5Ytet with G418 (300–500 mg/ml) and selected with blasticidin
(5 mg/ml). Antibiotic-resistant transfectants were isolated and
evaluated for tetracycline (Tet) (1 mg/ml) regulated CASZ1a or
CASZ1b expression. Stable clones expressing CASZ1a are labeled
SY5YtetCASZ1a, and stable clones expressing CASZ1b are
labeled SY5YtetCASZ1b. The stable clones with empty vector
are labeled SY5Ytetemv.
Western Blot and Indirect Immunofluorescence Assay
Protein extraction, western blot analysis and indirect immuno-
fluorescence assay were performed as described previously [7].
CASZ1 antibody (Rockland Immunochemical for Research)
recognizes both CASZ1a and CASZ1b isoforms. The affinity
purified rabbit polyclonal antibody was raised against a peptide
mapping with an internal region of CASZ1a (NP_001073312.1,
amino acid 923-936, sequence: HEASQDRSLDLTVK) of human
origin, and the peptide sequence is 100% conserved in mouse. For
Western Blot analyses, an anti–Flag (1:1000) antibody from Sigma,
antibodies to endogenous CASZ1 (1:2000) from Rockland, a-
tubulin (1:2000) from Santa Cruz were used to detect each protein
expression. For indirect immunofluorescent cell staining, cells were
incubated with anti- CASZ1 (1:500) or a-Tubulin (1:500)
(Molecular Probes) for 1 hr at room temperature, washed 3 times,
followed by incubation with goat anti-rabbit IgG-Alex 568 and
goat anti-mouse IgG-Alex 488 (1:300) (Molecular Probes) for
45 min at room temperature.
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The primer sets used for the realtime PCR were shown in
Table 3. Quantitative real-time PCR was performed on ABI
Prism 7000 (PE Applied Biosystems) using SYBR Green
SuperMix as described previously and b-Actin was used as
normalization control [7]. The PCR was performed in duplicate
or triplicate and repeated at least once. For the primary tumor
study, total RNA from neuroblastoma tumors from 59 patients
prior to chemotherapy was provided by the Children’s
Oncology Group (COG) Neuroblastoma Biology Group Com-
mittee. RNA (2 mg) was used as template for cDNA synthesis
using Superscript III (Invitrogen), and CASZ1a and CASZ1b
levels assessed by SYBR realtime PCR using CASZ1a and
CASZ1b specific primer sets. PCR reactions were performed
Figure 6. Like CASZ1a, CASZ1b suppresses neuroblastoma cell growth. A. Induction of CASZ1b by Tet in SY5YtetCASZ1b cells inhibited cell
growth, and the magnitude of inhibition was similar to CASZ1a in SY5YtetCASZ1a cells. The cell confluence was measured at different time point
using IncuCyte instrument (P,0.05 for all time points since day 2). B. Similar to CASZ1a, the induction of CASZ1b by Tet inhibited proliferation of
SY5YtetCASZ1b cells as assessed using a MTS assay on day 7 (p,0.005). C. Similar to CASZ1a, the induction of CASZ1b by Tet decreased clonogenicity
of SY5YtetCASZ1b cells in soft agar (p,0.005). D. SY5YtetCASZ1b cells were subcutaneously injected into nude mice. The induction of CASZ1b
expression significantly inhibited tumor growth in the xenograft model (n=5 mice per group, total 10 mice; Volume=long 6 short
2/4; data are
shown as mean 6 SEM, all time point p,0.02 since day 45).
doi:10.1371/journal.pone.0018557.g006
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and CASZ1b tissue distribution studies, tissuescan mouse
developmental qPCR array was used, which contains fist strand
DNA from 48 tissues at five stages and normalized to GAPDH
(OriGene Technologies).
Promoter activity assay
HEK293T cells were used for promoter activity assay. Cells in
24 – well plate were transfected using lipofectamine 2000
(Invitrogen) following the manufacturer’s protocol. Tyrosine
hydroxylase promoter – pGL4.1-luc construct (TH-luc) is
generously provided by Gregory Wray, which contains 2kb of
TH promoter [23]. A CMV-driven b-galactosidase construct
was co-transfected with TH-luc and pCMV-FLAG_CASZ1a or
pCMV-FLAG_CASZ1b in order to provide an internal control
for transfection efficiency. Luciferase activity was quantified after
24 hours using the Dual Luciferase Reporter Assay System
(Promega), and beta-galactosidase activity was measured con-
comitantly with the Luminescent Beta-galactosidase Detection
Kit II (Clontech). The experiments were repeated for three
times.
Cell proliferation and clonogenicity assays
To assess the effect of CASZ1 on neuroblastoma cell
proliferation, SY5YtetCASZ1a and SY5YtetCASZ1b cells were
plated into 24-well plate. The next day, Tet was added to the
RPMI-1640 containing 10% fetal calf serum. Cells were cultured
in the IncuCyte (ESSEN INSTRUMENTS) and cell confluence
was measured every 6 hr for 6 days using the IncuCyte software.
MTS assay was also applied to assess cell proliferation for both
SY5Y and AS cells that expressing CASZ1a or CASZ1b. To assess
effects of CASZ1a or CASZ1b on anchorage independent cell
growth, 1610
4 cells were cultured in 0.7% top agarose in media
containing G418 and Blasticidin (6 Tet) plated on a layer of 1.4%
bottom agar/RPMI to prevent the adhesion of cells to the culture
plates. Medium was changed 3x/week and visible colonies
counted after 4 weeks.
Animals
The animal studies were approved by the Animal Care and Use
Committee of the National Cancer Institute, and all animal
treatments, including their housing, were in accordance with
institutional guidelines (PB-023).
In vivo tumorigenesis
Suspensions of SY5YtetCASZ1b (2610
6 cells were mixed with
an equal volume of Matrigel solution (Trevigen) and implanted
subcutaneously in the dorsal flank of 10 SCID mice (6- to 8-week-
old female mice) per cell line. Control mice received regular food,
and the other half received doxycycline containing food for 1 week
prior to tumor implantation and during the course of the
experiment. The tumors were measured once a week, and
sacrificed once the tumor diameter reached 20 mm.
Statistical analyses
Patients were categorized as having low or high levels of
CASZ1b and CASZ1a expression based on whether their values
fell below or above the median. Stratification with regard to age
(,18 months vs. $18 months), INSS stage (not stage 4 vs. stage 4),
risk group (low & intermediate vs. high), MYCN status (not
amplified vs. amplified), Shimada histology (favorable vs. unfa-
vorable), ploidy (hyperdiploid vs. diploid), 1p LOH (no LOH vs.
LOH), and 11q LOH (no LOH vs. LOH) was examined. The
association of CASZ1b and CASZ1a expression levels with these
prognostic factors was examined via a two-sided Fisher’s exact test.
The method of Kaplan and Meier [24] was used to generate
survival curves, with standard errors per Peto et al. [25]. For EFS,
an event was defined as relapse, progression, secondary malig-
nancy, or death from any cause. For overall survival (OS), death
was the only event considered. The log-rank test was used to test
for differences between survival curves.
Additional statistical analyses of continuous data were per-
formed using a t-test. Values in the graphs are expressed as means
6 SEM or SD. The statistical tests were two-sided. P-values less
than 0.05 were considered statistically significant.
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